ter info, had hen meer info gevraagd ivm upcoming events.
Immutep are indeed participating at ESMO 2021, but not announcing new data. There are, however, posters and presentations from its partners and other key players in the LAG-3 space:
Novartis will present two posters including its PLATForM phase II study of novel spartalizumab combinations in melanoma, concluding patients with LAG-3+ melanoma may be more likely to respond to spartalizumab + ieramilimab (LAG525) treatment.
IKF will report final efficacy and safety data from the INSIGHT-004. Aligned with ASCO 2021 data, its poster reiterates further clinical evaluation of the combination of efti plus anti-PDL-1 therapy is warranted in distinct tumour indications.
Bristol Myers Squibb will deliver an oral session on its RELATIVITY-047 trial in melanoma. In June 2021, this trial reported encouraging Phase III results, which validated the interaction between LAG-3 and the MHC class II as a therapeutic mechanism for regulating the body's immune system to fight cancer.
Marc Voigt will be participating at Cantor this year. Its in a virtual format.